Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company InterMune has announced the pricing of its underwritten public offering of 3.5 million shares of newly issued common stock at a price to the public of $19.50 per share.
Subscribe to our email newsletter
InterMune has also granted the underwriters a 30-day option to purchase up to an additional 525,000 shares of common stock. All of the shares in the offering are being sold by InterMune.
Goldman, Sachs & Company is acting as the sole book-running manager of the offering. Deutsche Bank Securities is acting as co-lead manager and CIBC World Markets is acting as co-manager of the offering.